Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Kulke is active.

Publication


Featured researches published by M. Kulke.


European Journal of Cancer | 2015

6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial

Jonathan R. Strosberg; Edward M. Wolin; Beth Chasen; M. Kulke; David L. Bushnell; Martyn Caplin; Richard P. Baum; Erik Mittra; Timothy J. Hobday; A. Hendifar; Kjell Öberg; M. Lopera Sierra; Philippe Ruszniewski; D. J. Kwekkeboom

177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours : Results of the phase III NETTER-1 trial


Neuroendocrinology | 2018

Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

Jonathan R. Strosberg; Edward M. Wolin; Beth Chasen; M. Kulke; David L. Bushnell; Martyn Caplin; Richard P. Baum; Timothy J. Hobday; A. Hendifar; Kjell Öberg; Philippe Ruszniewski; E. Krenning

Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies : Subgroup Analysis of the GREPONET StudySelected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine TumorsSelected For Oral Presentation: Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms : A Retrospective International Multicenter StudySelected For Poster Walks : Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine TumorsA Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine TumorsPlasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment : The Nordic EXPLAIN Biomarker StudyIntravenous versus Oral Etoposide : Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)


UKI NETS 15th National Conference | 2017

Weight change associated with telotristat ethyl in the treatment of carcinoid syndrome

Martin O. Weickert; Gregory Kaltsas; Dieter Hörsch; Pablo Lapuerta; M. Pavel; Juan W. Valle; Martyn Caplin; Emily K. Bergsland; Pamela Kunz; Lowell Anthony; Enrique Grande; Kjell Öberg; Catherine Lombard-Bohas; Rosanna Fleming; Ashwin Kittur; Karie Arnold; M. Kulke; Staffan Welin; Richard R.P. Warner; Qi Yang

1University Hospitals Coventry and Warwickshire NHS Trust; 2Zentralklinik Bad Berka; 3Lexicon Pharmaceuticals, Inc.; 4Charité–Universitätsmedizin; 5Friedrich-Alexander-Universität; 6University of Manchester/The Christie NHS Foundation Trust; 7Royal Free Hospital; 8UCSF Helen Diller Family Comprehensive Cancer Center; 9Stanford University; 10University of Kentucky; 11Hospital Universitario Ramón y Cajal; 12Uppsala University; 13Icahn School of Medicine at Mount Sinai; 14Hôpital Edouard Herriot, Hospices Civils de Lyon; 15Dana-Farber Cancer Institute


Annals of Oncology | 2017

438PDImproved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial

Jonathan R. Strosberg; Edward M. Wolin; Beth Chasen; M. Kulke; David L. Bushnell; Martyn Caplin; Richard P. Baum; Pamela Kunz; Timothy J. Hobday; A. Hendifar; Kjell Oberg; M. Lopera Sierra; Philippe Ruszniewski; E. Krenning

Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE : The NETTER-1 phase III trial


Annals of Oncology | 2010

PROGNOSTIC AND PREDICTIVE VALUE OF CHROMOGRANIN A AND NEURON-SPECIFIC ENOLASE IN PATIENTS (PTS) WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) TREATED WITH EVEROLIMUS

Kjell Öberg; M. Kulke; M. Pavel; Alexandria T. Phan; Sakina Hoosen; J. St Peter; Azzeddine Cherfi; James C. Yao


Neuroendocrinology | 2015

A randomized open-label phase II study of Everolimus alone or in combination with Pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial

M. Kulke; Philippe Ruszniewski; E. Van Cutsem; Juan W. Valle; W. W. de Herder; M. Pavel; Evgeny Degtyarev; Du Hung Lam; Ramon Salazar; Ivan Borbath; Nicola Fazio; Catherine Lombard-Bohas; James C. Yao


Annals of Oncology | 2016

NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis

Jonathan R. Strosberg; Edward M. Wolin; Beth Chasen; M. Kulke; David L. Bushnell; Martyn Caplin; Richard P. Baum; Pamela Kunz; Timothy J. Hobday; A. Hendifar; Kjell Oberg; M. Lopera Sierra; D. J. Kwekkeboom; Philippe Ruszniewski; E. Krenning


Pancreas | 2017

Efficacy and safety results of telotristat ethyl in patients With carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial.

M. Pavel; David J. Gross; Marta Benavent; Martyn Caplin; Petros Perros; Raj Srirajaskanthan; Juan W. Valle; Richard R.P. Warner; M. Kulke; Lowell Anthony; Pamela Kunz; Dieter Hörsch; K Berg; Pablo Lapuerta; Shanna Jackson; Phillip Banks; Talia Biran; R. Garcia-Carbonero


Pancreas | 2017

Everolimus for advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract: efficacy and safety from a RADIANT-4 subgroup analysis.

Simron Singh; Carlo Carnaghi; R. Buzzoni; Markus Raderer; Harald Lahner; Juan W. Valle; Maurizio Voi; Lida Bubuteishvili Pacaud; Jeremie Lincy; Natsuko Okita; M. Kulke; Jonathan R. Strosberg; James C. Yao; M. Pavel; Nicola Fazio


UKI NETS 14th National Conference | 2016

Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews

Lowell Anthony; Dieter Hörsch; Claire Ervin; M. Kulke; M. Pavel; Emily K. Bergsland; Martyn Caplin; Kjell Oberg; Richard R.P. Warner; Pamela Kunz; David C. Metz; Janice L. Pasieka; Nick Pavlakis; Dana B. DiBenedetti; Emily Haydysch; Qi Melissa Yang; Shanna Jackson; Karie Arnold; Linda Law; Pablo Lapuerta

Collaboration


Dive into the M. Kulke's collaboration.

Top Co-Authors

Avatar

M. Pavel

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Martyn Caplin

Royal Free London NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pamela Kunz

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Richard P. Baum

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar

Beth Chasen

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Juan W. Valle

University of Manchester

View shared research outputs
Researchain Logo
Decentralizing Knowledge